Thromboembolism

06/12/2000 - "Warfarin sodium therapy is highly effective in preventing thromboembolism. "
02/15/2014 - "Decision to restart warfarin after an episode of major GIB is associated with improved survival and decreased thromboembolism without increased risk of GIB after 7 days of interruption."
04/01/2012 - "For AF, DE 150 mg BID orally is superior to warfarin in the prevention of thromboembolism, whereas 110 mg BID is noninferior to warfarin. "
09/01/2010 - "Although warfarin is effective in preventing thromboembolism, its use is limited by its narrow therapeutic index that necessitates frequent monitoring and dose adjustments resulting in considerable inconvenience to patients and clinicians. "
07/01/2013 - "Warfarin is effective for the prevention and treatment of thromboembolism but produces variable anticoagulant effects and requires routine monitoring of the international normalized ratio (INR) to optimize the balance between efficacy and safety. "

08/15/1998 - "There is growing evidence on the superior efficacy and safety of low molecular weight heparins (LMWHs) over unfractionated heparin (UFH) for the treatment of both venous and arterial thromboembolism. "
08/01/2005 - "Heparin has been the mainstay of treatment and prevention of venous and arterial thromboembolism for many years. "
05/01/1996 - "Subcutaneous LMW heparin is as effective as UF heparin for prophylaxis of thromboembolism in bedridden, hospitalized medical patients."
01/01/1986 - "Two-thirds of the dose of heparin were identically effective in prevention of venous thromboembolisms than the whole dose if heparin was combined with DHE. "
01/01/1983 - "This suggests that heparin therapy would be effective in preventing thromboembolism in this disorder. "

07/01/1976 - "We conclude that the use of an anticoagulant plus aspirin is a good and safe therapy for the prevention of thromboembolism in these patients."
02/06/1996 - "Aspirin may be a valid alternative in young patients without cardiopathy; however, anticoagulation is more effective in patients which have experienced thromboembolism. "
08/01/2014 - "The increasing prescription of low-dose aspirin and other antithrombotic drugs for protection against thromboembolism to many patients admitted to hospital may increase the vulnerability of a wider group to NVGIB. "
12/01/2013 - "Aspirin in the secondary prevention of unprovoked thromboembolism: the WARFASA and ASPIRE studies."
12/01/2013 - "Based on the evidence presented, the authors recommend using aspirin only after bioprosthetic aortic valve replacement in patients at low risk of thromboembolism."

08/15/1997 - "Further study to evaluate the safety and efficacy of low-molecular-weight heparin for both prophylaxis and treatment of thromboembolism in association with malignancy may lead to decreased morbidity and better quality of life for patients with this disorder."
10/01/2013 - "We try to answer the question whether the choice of low-molecular-weight heparin influences the compliance with the S2 guideline "Inpatient and outpatient thromboembolism prophylaxis in surgery and perioperative medicine." Beyond that we ask if multi-dose administration is superior to the pre-filled syringe when total costs are calculated on the basis of procedure and technical application. "
12/01/2001 - "Low molecular weight heparin and external pneumatic compression are similarly effective in the postoperative prophylaxis of thromboembolism. "
04/01/2005 - "Low-molecular-weight heparin thus appears safe and effective for treating thromboembolism in nephrotic patients."
03/01/2002 - "The purpose of this study was to determine the incidence of DVT, to demonstrate the efficacy of a perioperative and postoperative prophylaxis against thromboembolism with use of low--molecular weight heparin (LMWH), and to show the safety and feasibility of LMWH administration. "

10/22/2012 - "Anticoagulant drugs are highly effective for the prevention and treatment of venous and arterial thromboembolism. "
10/01/2011 - "Conventional anticoagulants have proven efficacy in the management of thromboembolism. "
11/01/2014 - "Good results of new anticoagulant drugs in trials in term of thromboembolism recurrence prevention may change established habits in TD patients with long term treatment."
07/01/1977 - "It is concluded that ASA combined with anticoagulants offered a significantly better protection against arterial thromboembolism than did anticoagulant therapy alone."
09/01/2013 - "A number of target-specific oral anticoagulants (TSOAs) have been developed in recent years, and some have shown considerable promise in large-scale, randomized clinical trials in the prevention and treatment of thromboembolism. "

04/01/2005 - "Enoxaparin was safe and effective for preventing thromboembolism and adverse obstetrical complications in our patients, including 12 of 13 multiple gestation pregnancies."
05/01/2002 - "The efficacy of enoxaparin in the management of venous and arterial thromboembolism has been shown in a wide range of patient groups using doses ranging from fixed doses of 20 - 60 mg o.d. "
12/01/2013 - "All studies enrolled patients with various risk factors for thromboembolism and evaluated different enoxaparin dosing regimens. "
06/01/2013 - "Benefits and risks of preventing thromboembolism with enoxaparin in patients with general surgery in real world--the CLEVER study."
03/01/2013 - "The aim of this study was to compare the efficacy and tolerability of enoxaparin for preventing thromboembolism after surgery in the out-patient and in-hospital settings. "

01/01/2015 - "Moderate quality evidence that patient self-monitoring is more effective than other forms of monitoring degree of anticoagulation with vitamin K antagonists, reducing the relative risk of thromboembolism by 41% and death by 34%. "
01/01/2015 - "Since in the early 1960s, oral anticoagulation with vitamin K antagonist are the gold-standard for prevention of thromboembolism at replaced heart valves. "
11/01/2015 - "Patients deemed to be at a high risk for arterial thromboembolism should be advised to take an oral anticoagulant with a vitamin K antagonist or a target-specific oral anticoagulant unless contraindicated. "
08/01/2015 - "The majority of mutations cause resistance to 4-hydroxycoumarin- and indandione-based vitamin K antagonists (VKA) used in the prevention and therapy of thromboembolism. "
05/01/2015 - "Since decades, oral anticoagulation (OAC) with vitamin K antagonists (VKA) is an established therapy for both prevention and treatment of thromboembolism in daily clinical routine. "

12/01/2004 - "This oral direct thrombin inhibitor is a potentially promising treatment option for the prevention of thromboembolism."
06/01/2014 - "Our data suggest a new mechanism of platelet activation which has the potential to increase risk for thromboembolism in patients with active CD which might be due to platelets poised for thrombin-inducible activation."
03/01/2014 - "Thrombin injection is costly and may cause thromboembolism. "
11/01/2013 - "Inhibition of thrombin is therefore an effective therapeutic target to prevent the formation of blood clots and related thromboembolism disorders. "
11/01/2012 - "Recent availability of direct thrombin inhibitor provides an alternative option of systemic anticoagulation in various thromboembolism conditions. "

06/28/2013 - "Aegyptin inhibits collagen-induced coagulation activation in vitro and thromboembolism in vivo."
01/01/1991 - "It is postulated that this difference is a function of the size of the collagen fibrils in the bioprostheses and that this accounts for the very low incidence of clinically evident thromboembolism in patients with implanted dura mater valves."
08/05/2002 - "Thus, cPLA(2)alpha plays a discrete role in the collagen-stimulated production of TX and its inhibition has a therapeutic potential against thromboembolism, with potentially limited bleeding expected."
01/01/2004 - "Oral doses of LFM-A13-F dose dependently prevented collagen-induced thromboembolism in mice without causing bleeding. "
01/01/2005 - "These include collagen vascular diseases, chronic thromboembolism, human immunodeficiency virus, portopulmonary hypertension, and other diseases. "

02/19/2003 - "Ximelagatran is currently under investigation for the prevention and treatment of thromboembolism. "
08/01/2009 - "Despite its subsequent withdrawal, clinical trials of ximelagatran demonstrated the efficacy of fixed doses of an oral, direct thrombin inhibitor for prevention of thromboembolism. "
09/01/2003 - "The program, the largest conducted in this indication, will determine the safety and antithrombotic efficacy of ximelagatran as an alternative to warfarin for prevention of thromboembolism in patients with AF."
09/01/2004 - "Further randomized trials are clearly needed, while current data suggest that ximelagatran will be able to represent a future viable therapeutic option for prevention of thromboembolism in patients with NRAF, offering huge advantages with respect to classic oral anticoagulants."
09/01/2010 - "Investigators concluded that ximelagatran was effective compared with well-controlled warfarin for prevention of thromboembolism. "

05/01/1976 - "The results indicate that cloth-covered prostheses have significantly lowered the incidence of thromboembolism and eliminated poppet dysfunction. "
04/01/1984 - "Long-term survival with this prosthesis is similar to that in more recent studies, and rates of thromboembolism and malfunction compare favorably with other prosthetic valves."
02/01/1977 - "In this study, the Smeloff-Cutter mitral prosthesis proved to be superior to the toroidal valve because of a lower incidence of thromboembolism."
01/01/2014 - "The linearized frequency of occurrence of thromboembolism were higher in patients with mono leaflet prosthesis. "
06/01/2013 - "Because of the high risk of thromboembolism, the patient underwent urgent surgery to remove the clot and to replace the mitral valve with a mechanical prosthesis. "

03/01/2003 - "Selective thrombolytic therapy appears to be effective in the treatment of mesenteric thromboembolism particularly in elderly patients with a high operative risk. "
05/01/1994 - "Selective thrombolytic therapy appears effective in the treatment of mesenteric thromboembolism, particularly in elderly patients with a high operative risk."
10/01/1993 - "Direct thrombolytic therapy is considered to be an effective treatment for thromboembolism following prosthetic valve replacement in certain selected cases."
12/17/2013 - "rt-PA is both safe and effective for the thrombolytic therapy of vena caval thromboembolism."
04/01/2007 - "Based on this and other reports, thrombolytic therapy may be effective and safe in patients with acute, non-organized LA thrombi and post hoc heparinization should be sufficient to prevent thromboembolism from rebound coagulation."

06/01/2007 - "Our clinical experience with more than 5000 total hip arthroplasties performed during the last decade and closely followed prospectively for a minimum of 3 months clearly shows this multimodal prophylaxis is safe and effective resulting in a very low prevalence of thromboembolism."
05/01/1999 - "The use of intraoperative and postoperative thigh-high intermittent pneumatic compression, combined with duplex ultrasonography performed by experienced vascular technologists, is effective for prophylaxis against thromboembolism after both primary and revision total hip arthroplasties. "
05/01/1999 - "The purpose of the present study was to evaluate the efficacy of intermittent pneumatic compression as prophylaxis against thromboembolism following total hip arthroplasty. "
05/01/1999 - "Efficacy of prophylaxis against thromboembolism with intermittent pneumatic compression after primary and revision total hip arthroplasty."
10/01/1977 - "A prospective study was undertaken in order to test the efficacy of intermittent calf compression for prevention of thromboembolism in patients undergoing total hip arthroplasty. "

10/15/2008 - "Prospective and randomized studies are still needed to establish more definitive evidence regarding the prevention of thromboembolism for bioprostheses."
01/01/2014 - " According to the Japanese Circulation Society guidelines, a bioprosthesis is recommended for aortic valve replacement (AVR) in patients aged ≥65 years who have no risk factors for thromboembolism. "
08/01/2011 - "The risk of thromboembolism was higher in patients with a bioprosthesis."
05/01/2005 - "The advantage of bioprostheses compared with mechanical valves is the freedom from thromboembolism; and therefore, the avoidance of long-term anticoagulation therapy. "
06/01/2004 - "Mechanical valves were significantly more prone to thromboembolism, whereas bioprostheses suffered structural valve deterioration. "

04/01/2009 - "Thromboembolism is a well-known phenomenon with endovascular stenting that may be improved with evolution in stent technology. "
01/01/2008 - "Further studies are warranted to identify any potential relationship between post-stent hyperactive platelets and thromboembolism."
07/01/2014 - "Ocular thromboembolism may be a risk of stent-assisted coiling when the stent traverses the orifice of the ophthalmic artery or the stent is placed in the C3 internal carotid artery. "
02/01/2014 - "Further, stent assisted coiling can reduce the incidence of complications that sometimes result from embolic coiling (e.g., neck remnants and thromboembolism). "
09/01/2013 - "We evaluated whether use of oral anticoagulation (OAC) was associated with any benefit in morbidity or mortality in patients with AF, high risk of thromboembolism (TE) (CHA2DS2-VASC score ≥ 2) and coronary stent implantation. "